NHS set to save £150 million by switching to new versions of most costly drug
Health chief Simon Stevens has today asked NHS hospitals to ensure they are ready to realise savings of up to £150 million a year to reinvest in frontline care after the patent on the NHS’s most costly drug ends this week.
Adalimumab is the single medicine on which hospitals spend the most, at a cost of more than £400 million a year.
More than 46,000 patients are prescribed the drug, which is only currently available under the brand name Humira®, for hospital treated, serious conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
However, doctors are now being asked to also consider equally effective, safe, ‘biosimilar’ versions of Adalimumab after the exclusive patent on the drug expires on Tuesday 16th October.
NHS England has issued guidance to Trusts and CCGs telling them that nine out of 10 new patients should be started on the best value medicine within three months of a biosimilar launch. At least 80% of existing patients should be switched to the best value biologic (which could be the originator or a biosimilar) within 12 months.
Biosimilar versions of Adalimumab are expected to be available to NHS patients from December this year, and could help save at least £150 million per year by 2021 depending on the price agreed for the drugs. The ongoing use of Humira® may also continue where clinically appropriate and where it is best value.
NHS England’s chief executive Simon Stevens said: “Biosimilar versions of widely used, expensive drugs are already delivering safe, effective treatment for patients across the NHS, including those with cancer.
“Adalimumab is the NHS’s biggest spend on a single drug and, as the NHS develops the long term plan, we want more clinicians to switch to use the best value biologics which will free up hundreds of millions of pounds to reinvest back into patient care.”
Last year the NHS spent £17.4bn on medicines, an increase of one third since 2010/11.
NHS England recently announced plans to accelerate and widen the uptake of biosimilars in a bid to save up to £300m a year by 2021. In 2017-18, the NHS saved over £200 million by using more biosimilar medicines.
Up to four adalimumab biosimilars could be available by the end of the year.
NHS Improvement’s director of hospital pharmacy Andrew Davies said: “We’ve had some excellent uptake of existing biosimilars so far which means more patients get access to high-quality, effective medicines and the NHS can reinvest savings into frontline care.
“The launch of biosimilar adalimumab will be the fifth major class of biosimilar launched for wider NHS use, and preparations have been put in place to make sure that more patients are able to receive this treatment as quickly as possible.”
Increasing choice of better value drugs is the latest example of ‘smart procurement’ by NHS England, aimed at making treatments and medicines available to more patients by driving down costs.
The National Rheumatoid Arthritis Society, National Ankylosing Spondylitis Society, Psoriasis Association and Crohn’s & Colitis UK are supporting NHS England’s plans to widen the uptake of biosimilars.
In a joint statement, they said: “We welcome the increased availability of effective treatment options for patients and understand the importance of the wise and careful use of NHS resources. Our organisations have been working to provide patient information and support since 2014 and are familiar with the evidence to date which reinforces the fact that biosimilars are as safe and effective as the reference products. The introduction of biosimilars for adalimumab brings opportunities for both patients and the NHS.”
Latest News from
NHS to provide life changing glucose monitors for Type 1 diabetes patients14/11/2018 14:15:00
Tens of thousands of people with Type 1 diabetes across the country will benefit from life changing glucose monitors on the NHS.
Speaking up in support of self care14/11/2018 09:15:00
A group of senior health professionals have thrown their support behind Self Care Week 2018.
Encouraging people to choose self care for life13/11/2018 12:15:00
More than 22 million people are being targeted as part of Self Care Week which launched yesterday.
NHS leaders commit to specialist health support for veterans in every part of NHS12/11/2018 16:15:00
NHS leaders recently recently confirmed that specialist health support for veterans will be available in every part of the health service, across the country.
Instant messaging services a “vital part of the NHS toolkit” during a crisis12/11/2018 09:15:00
New guidance for the NHS will help doctors, nurses and other staff use instant messaging safely to co-ordinate patients’ care during emergencies.
England’s top doctor calls on NHS to use tech to revamp outpatient system09/11/2018 16:15:00
England’s top doctor is calling on the NHS to enlist the power of tech and innovation to reduce the thousands of unnecessary outpatient appointments carried out every day.
Advice line for GPs saves hours of travel for patients and £100k to be reinvested back into NHS05/11/2018 09:15:00
A neurology hotline for GPs in the north west has spared patients unnecessary worry and travel time, while £100,000 a year has been reinvested back into the NHS.
Families of over 300 children avoid driving 30,000 miles for appointments thanks to new hospital alliance15/10/2018 09:15:00
The families of over 300 children with epilepsy and other neurological diagnoses have avoided having to travel nearly 30,000 miles of hospital trips after two hospitals joined forces to provide care closer to home.